If you've already tried the higher-yield options for sleep or anxiety and want to try this anyway, the realistic version is to buy from a brand publishing third-party lab results, take roughly ten times the gummy dose, give it four weeks, and — this is the one that matters — tell whoever prescribes your other medications. The drug-interaction risk is the under-discussed half of this category.
CBD is the non-intoxicating cannabinoid from hemp — same plant family as the one that gets you high, none of the high. It does not bind the receptors that THC binds. What it does instead is touch a lot of things weakly: a calming serotonin receptor (the same one the anti-anxiety drug buspirone uses), a heat/pain receptor on nerve endings, and a handful of others. Broad and weak across many targets is consistent with both the broad list of things it's marketed for and the fact that the doses that produced effects in trials were large.
The mechanism that matters most clinically isn't the calming one — it's that CBD slows down the liver enzymes that break down a lot of other drugs. The enzyme family is called cytochrome P450, and it clears roughly 60% of prescription medications. CBD inhibits several of the busiest ones. In a published epilepsy trial, adding CBD raised the active form of an anti-seizure drug called clobazam in the blood by roughly five-fold, enough to require cutting the clobazam dose Geffrey 2015. The same mechanism is general — it can affect statins, antidepressants, blood thinners, transplant medications, and some chemotherapy drugs Brown and Winterstein 2019. "Non-intoxicating" doesn't mean inert. It is a real drug, and it acts like one.
What's actually been shown — and at what dose
There is one clean signal in the CBD literature, and it is not the one being sold. Two large trials in children with rare, severe epilepsies showed that purified CBD cut convulsive seizures by about 40%. That product is a prescription drug called Epidiolex; the doses used were 10–20 mg per kilogram of body weight per day — for an adult, that's 700–1,400 mg, taken every day, under a neurologist. The FDA approved it on this evidence. Nothing on a CBD shelf comes close to that dose, that supervision, or that level of evidence.
For anxiety — the most common reason people buy CBD — the foundational trial dosed 600 mg in a single sitting, gave it to 24 patients with social phobia ninety minutes before a simulated public-speaking test, and measured a real reduction in anxiety, discomfort, and cognitive impairment scores Bergamaschi 2011. A follow-up testing 100, 300, and 900 mg found the curve was upside-down: 300 mg helped, 100 and 900 didn't Linares 2019. So the studied effective window for acute anxiety is roughly 300–600 mg in one dose. A typical retail gummy is 10–25 mg. The most-cited consumer sleep study isn't an RCT — it's an uncontrolled case series of 72 patients prescribed 25–175 mg daily by the publishing doctor; sleep improved in 67% short-term and then fluctuated Shannon 2019. The 2019 Lancet Psychiatry systematic review of cannabinoids for mental disorders concluded the evidence for CBD as a treatment for primary anxiety is insufficient to make a recommendation Black 2019. For chronic pain, the Cochrane review on cannabis-based medicines rated the evidence low quality, and even that weak signal came from products containing THC, not CBD alone Mücke 2018.
One line summary: real evidence at pharmaceutical doses for a niche indication; small real evidence for acute anxiety at hundreds of milligrams; almost nothing of trial quality at the doses being sold for the reasons being sold.
Three things the bottle won't tell you
The dose on the label is often wrong. A JAMA analysis of 84 CBD products bought online found 31% accurate (within 10% of label), 43% containing more CBD than stated, and 26% containing less — and 21% contained detectable THC despite being marketed as hemp Bonn-Miller 2017. A 2022 follow-up on topical creams sold at national chains found roughly three-quarters were inaccurately labelled Spindle 2022. The category is essentially unregulated; the FDA has said outright that it cannot currently approve CBD as a supplement under existing rules and has asked Congress for a new pathway FDA 2023.
"Natural" doesn't mean safe to combine with your other medications. The cytochrome interaction described above is the practical version of this: people on warfarin, certain epilepsy drugs, several statins, transplant medications, and many cancer drugs can have their plasma drug levels move unpredictably when CBD is added, often without anyone noticing because the patient never mentioned it. The Epidiolex trials also showed liver enzyme elevation (ALT above three times the upper normal limit) in a meaningful fraction of patients on therapeutic doses — and a phase I trial in healthy adults at high doses replicated the liver signal without polypharmacy as an excuse Watkins 2021.
"Studied for anxiety and sleep" almost always means studied at doses you aren't taking. When a marketer cites a trial, check the dose. If it's 300 or 600 mg in a single sitting and you're taking 15 mg nightly, the trial is not evidence for what you're doing — it's evidence that something else, at a much larger dose, did something measurable once.
If you're going to try it, do it like a trial
The default consumer pattern — a 10–25 mg gummy every night, no end date, no benchmark, no conversation with anyone — is the pattern least likely to produce a real answer. If the question is "does CBD help me," the only way to find out is to give it a shot at a dose and duration that resembles what worked in the literature, then stop and see.
One practical note on cost: at typical pricing of about $0.05–$0.30 per milligram, a 100 mg/day four-week trial runs roughly $40–$250. A nightly 25 mg gummy at the same pricing is roughly $200–$800 a year. The "studied" dose for anxiety, taken daily for a year, runs into four figures.
When CBD is genuinely a bad idea
Pregnancy and breastfeeding: there isn't enough human safety data, animal data has flagged signals at high doses, and the FDA advises against. Existing liver disease is a separate caution because of the consistent transaminase signal at therapeutic doses. And one practical one that catches people: many "hemp" products contain enough residual THC to produce a positive workplace drug screen Bonn-Miller 2017 — if your job tests, the only reasonable approach is broad-spectrum or isolate product with a current third-party COA showing non-detectable THC.
What actually works for the thing you're buying CBD for
For insomnia, the gold-standard treatment is a structured behavioural programme called CBT-I — cognitive behavioural therapy for insomnia. The evidence base is large, the effects last after the treatment ends, and digital versions are now widely available. Conventional sleep hygiene (consistent wake time, dark room, no caffeine after noon, morning daylight) earns its keep too. Where pharmacology is needed, a clinician-led trial of an evidence-backed agent will out-perform any consumer CBD product.
For anxiety, cognitive behavioural therapy and SSRIs are first-line and have decades of RCT evidence; exercise has surprisingly large effects on anxiety in trials. For acute situational anxiety (the public-speaking case the CBD trials modelled), short-acting agents under a doctor are an option, as is propranolol for the physical-symptom side.
For chronic pain, the highest-leverage interventions are usually unsexy: graded exercise, physical therapy, sleep, and where appropriate, NSAIDs or duloxetine under clinician care. Where cannabinoids are genuinely useful for pain, the trials that show effect mostly used products containing THC, not isolate CBD Mücke 2018 — which is a separate clinical decision with separate tradeoffs.
Why "I tried it and it didn't work"
When CBD doesn't work for someone, it's almost always one of four things, in roughly this order:
- The dose was too low. A 10 mg gummy is roughly one-sixtieth of the trial dose that produced acute anxiolysis. The user is doing the equivalent of testing whether a sip of beer makes them drunk.
- The product contained less CBD than the label claimed. Roughly one in four products is overlabelled Bonn-Miller 2017; without a third-party lab certificate, the buyer has no way to know.
- It was placebo all along, and the placebo wore off. Wellness purchases buy a real expectancy effect at the start. Two to three months in, when the novelty fades, the perceived effect goes with it.
- It was working, but on the wrong thing. A real but small drug-interaction effect can quietly raise plasma levels of another medication and produce side effects the user attributes to anything but the CBD.
The reason a properly-conducted four-week trial at a real dose, from a third-party-tested product, with the prescriber informed, is the right protocol: it makes all four of these failure modes visible.
The market you're actually buying in
Federally in the US, hemp-derived CBD with less than 0.3% THC has been legal since the 2018 Farm Bill; state law varies, and a handful of states still restrict it. The FDA has explicitly declined to regulate consumer CBD as a dietary supplement and has asked Congress for a new framework FDA 2023 — which means there is no agency checking, at the shelf, whether the bottle's label matches its contents or whether the manufacturing meets any specific standard. The voluntary substitute is third-party lab testing — a few large independent labs (ISO 17025-accredited) issue per-batch certificates, and the better brands publish them. The certificate is the only thing standing between you and the labelling distribution described above.
Pricing varies enormously by form factor: tinctures and isolates per milligram are cheaper than gummies, which are cheaper than topicals per active ingredient. A reasonable rule of thumb is $0.05–$0.30 per mg CBD. Insurance covers nothing on the consumer side; the prescription form (Epidiolex, for specific paediatric epilepsies) is covered when prescribed for its approved indication and not otherwise.
What keeps quietly happening if nothing changes
Day to day, very little — and that's the point. The nightly gummy keeps coming out of the bottle, the sleep keeps being roughly what it was, and the anxiety keeps being roughly what it was, because nothing at that dose was going to move either much. What changes silently is the bank balance: a couple of hundred to a couple of thousand dollars a year, transferred from a household to a retailer for a benefit the trial literature doesn't support at the dose being taken. Multiply by two or three years of habit and the number gets serious in a way no single purchase ever felt.
The clinical version is rarer but sharper. Somewhere out there is a patient on a blood thinner whose INR drifted the month they started a tincture, or a transplant patient whose tacrolimus levels climbed quietly, or a chemotherapy patient on a CYP3A4-cleared regimen whose plasma drug exposure shifted without anyone knowing. Most of those people never told their prescriber about the CBD because "it's natural" reads as a category outside the prescription-disclosure list. The medication change that didn't happen, the dose that didn't get adjusted, the side-effect attributed to something else — these are the stakes that don't show up in marketing copy.
And the second-order one: a person who keeps trying CBD for sleep for two years is, by definition, a person who has not done CBT-I or had the prescriber conversation in the same two years. The opportunity cost of an indefinite ineffective trial is the effective trial they didn't run.
What's actually on offer when you do this right
Two honest payoffs, on different timescales.
If you don't use it. A few hundred to a few thousand dollars a year stays in your account. The next time a wellness category appears in your social feed, you catch yourself looking for the dose comparison before you reach for your card — which is a piece of pattern-recognition you keep for the next ten years, across every supplement category that gets invented. The bottle on the kitchen counter goes away; the sleep and anxiety you had before the bottle are still there to address with the things that actually work for them.
If you do use it, the right way. A bounded four-week trial at a real dose gives you a clean answer in a month. If it worked, you know — and you continue with eyes open, third-party-tested product, prescriber informed, dose at a level the trials would recognise. If it didn't, you know that too, and you stop, and the bottle doesn't keep silently selling itself to you for the next two years. Either way you exit the experiment with information, which is what most of the people who have been using it nightly for years still don't have.
For the small group who actually needs purified CBD at therapeutic doses — patients with treatment-resistant childhood epilepsies on Epidiolex under a neurologist — the payoff is well-documented, much larger, and not what this entry is about Devinsky 2017.
Adjacent areas worth a look if this entry sent you down the rabbit hole: cognitive behavioural therapy for insomnia (CBT-I), the underused first-line for sleep complaints; the broader question of how to evaluate a wellness supplement for label accuracy and dose-versus-evidence gap before buying; and clinician-supervised medical cannabis for chronic pain or specific neurological indications, which is a different drug with a different evidence base. The 2018 Farm Bill loophole has also spawned a class of hemp-derived intoxicants (Δ8-THC, HHC) sold in similar packaging — that's a separate category with very different risks.
Substance and claimed effects
Cannabidiol (CBD) is a non-intoxicating cannabinoid from Cannabis sativa, isolated from hemp (legally defined in the US as cannabis with <0.3% THC by dry weight). It is sold consumer-side as oils/tinctures, gummies, capsules, vaped concentrates, beverages, and topical creams/balms. Pharmaceutically, purified CBD (Epidiolex) is FDA-approved as an add-on anticonvulsant for Dravet syndrome, Lennox-Gastaut syndrome, and tuberous sclerosis complex Devinsky et al. 2017Devinsky et al. 2018. Consumer-side, manufacturers and retailers promote it for anxiety, insomnia, chronic pain, inflammation, and a long tail of additional conditions (PTSD, addiction, acne, "general wellness"). This entry covers the substance and its meaningful consequences for the typical retail user: the evidence behind the three flagship claims (anxiety, sleep, pain), the multi-order dose gap between studied and retail amounts, drug interactions via cytochrome P450 enzymes, label-accuracy and contamination data on actual products, and the safety profile at therapeutic exposure. Out of scope: medical cannabis with meaningful THC, the seizure indications (Epidiolex is a prescription drug, not a consumer product), and topical cosmetic claims where the cannabinoid is incidental marketing on an otherwise ordinary moisturiser.
Evidence by addressing question
mechanism
CBD does not bind cannabinoid CB1 or CB2 receptors with meaningful affinity — which is why it is non-intoxicating, unlike THC. Its activity is promiscuous and weak across many targets: partial agonism at serotonin 5-HT1A receptors (the proposed anxiolytic route, shared by buspirone), negative allosteric modulation of CB1, agonism at TRPV1 (the capsaicin / heat receptor, relevant to pain modulation), GPR55 antagonism, and inhibition of fatty acid amide hydrolase (raising endogenous anandamide) WHO 2018Iffland & Grotenhermen 2017. None of these affinities is high; the mechanistic story is "broad, weak modulation across many systems," which is consistent with both the broad claims spectrum and the steep dose requirements seen in trials.
Crucially, CBD is metabolised by — and inhibits — the same cytochrome P450 enzymes that clear roughly 60% of prescribed drugs. In vitro and in vivo, CBD inhibits CYP3A4, CYP2C19, CYP2C9, CYP2D6, CYP1A2, and CYP2B6, with CYP2C19 inhibition being especially robust at therapeutic doses Stout & Cimino 2014Brown & Winterstein 2019. The clinical signal is real: in epilepsy trials, CBD coadministration raised plasma N-desmethylclobazam (the active clobazam metabolite) by roughly 500% via CYP2C19 inhibition, requiring clobazam dose reduction Geffrey et al. 2015. Warfarin INR rose unpredictably in case reports of CBD users on stable doses Damkier et al. 2019. The mechanism is general — anything CYP3A4 or CYP2C9/2C19 metabolises (statins, SSRIs, tacrolimus, oral anticoagulants, many antiepileptics, some chemotherapeutics) is in scope.
evidence
The clean signal is in epilepsy: two NEJM RCTs showed Epidiolex (purified CBD, 10–20 mg/kg/day, i.e. ~700–1400 mg/day in adults) cut convulsive seizures by ~39–46% in Dravet and Lennox-Gastaut syndromes Devinsky et al. 2017Devinsky et al. 2018. These are real, replicated, FDA-approved-strength data — but they are at doses two to three orders of magnitude above retail gummies (5–25 mg/serving) and the indication is paediatric epilepsy, not anxiety/sleep/pain.
For anxiety, the strongest single trial is Bergamaschi 2011: 24 social-phobia patients took 600 mg CBD or placebo 90 minutes before a simulated public-speaking test; CBD significantly reduced the anxiety, cognitive impairment, and discomfort scores on the visual analogue mood scale, with effects approaching those of healthy controls Bergamaschi et al. 2011. Crippa 2011 (n=10) showed CBD 400 mg altered cerebral blood flow in anxiety-relevant regions Crippa et al. 2011. Linares 2019 ran a dose-response — 100/300/900 mg — in the same public-speaking model and found an inverted-U: 300 mg helped, 100 and 900 mg did not Linares et al. 2019. The 2019 Lancet Psychiatry systematic review of cannabinoids for mental disorders concluded the evidence for CBD as anxiolytic in primary anxiety disorders is insufficient to make recommendations Black et al. 2019.
For sleep, the headline study most consumer marketing cites is Shannon 2019 — a retrospective case series of 72 psychiatric outpatients prescribed 25–175 mg/day CBD; anxiety scores fell in 79% within a month and sleep scores improved in 67% initially but fluctuated thereafter Shannon et al. 2019. This is uncontrolled, unblinded, single-site, and prescribed by the publishing author — a hypothesis-generating series, not evidence of efficacy. RCT-grade sleep data at consumer doses essentially does not exist.
For pain, the Cochrane review of cannabis-based medicines for chronic neuropathic pain rated the evidence low-to-very-low quality and the number needed to treat for 30% pain relief at ~11 (vs. NNH ~3 for nervous-system adverse events) — and even that signal was driven by THC-containing products, not isolate CBD Mücke et al. 2018. A large fibromyalgia self-report survey found ~30% of users said CBD helped pain enough to reduce opioids, but this is uncontrolled patient testimony with substantial selection bias Boehnke et al. 2022. The 2017 National Academies cannabis report flagged moderate evidence for the cannabis plant as a whole in chronic pain — and explicitly noted CBD-isolate evidence is thin NAS 2017.
protocol
The dose gap is the story. Trials showing effect run 300–600 mg/day for anxiety, 25–175 mg/day in the Shannon sleep case series, and 10–20 mg/kg/day (~700–1400 mg) for the epilepsy indication. Retail gummies and tinctures usually deliver 5–25 mg per serving; an average consumer using a labelled-25 mg gummy nightly takes roughly 1/12th to 1/24th of the lowest-arm anxiety dose Larsen & Shahinas 2020. To reach Bergamaschi's 600 mg, that consumer would need 24 gummies a night — at typical pricing, roughly $30–$60. Oral bioavailability is also low (~6–19%) and food-dependent — a high-fat meal can raise plasma exposure roughly 4-fold versus fasting Birnbaum et al. 2019; vaping reaches higher peak concentrations faster but with much shorter duration Spindle et al. 2020. Topical bioavailability is poorer still and almost certainly subclinical for systemic effects; topical CBD's plausible mechanism is local (joint, skin), not central.
contraindications
CYP-mediated drug interactions are the highest-leverage concern. The Epidiolex label and CBD's pharmacology imply meaningful interactions with: warfarin and direct oral anticoagulants (bleeding risk) Damkier et al. 2019, clobazam and other CYP2C19-cleared antiepileptics Geffrey et al. 2015, several statins (raised plasma levels → myopathy), SSRIs (especially those CYP2C19/2D6-dependent), tacrolimus (transplant immunosuppression), and many chemotherapeutics Brown & Winterstein 2019. The Epidiolex pivotal trials showed dose-dependent transaminase (ALT) elevation >3× upper limit of normal in roughly 5–20% of patients, mostly in combination with valproate; a phase I trial of healthy adults at therapeutic doses found liver chemistry abnormalities (ALT elevation) in a measurable fraction even without polypharmacy Watkins et al. 2021. Pregnancy and breastfeeding: insufficient human data; FDA advises against. THC contamination of consumer products can produce positive workplace drug tests and, in rare cases, intoxication Bonn-Miller et al. 2017.
misconceptions
Three common ones. First: "CBD is well-studied for anxiety/sleep/pain" — the studied population is overwhelmingly paediatric epilepsy at pharmaceutical doses, with small acute-anxiety trials at hundreds of milligrams; chronic-anxiety and sleep RCTs at consumer doses are absent Black et al. 2019. Second: "CBD is natural and therefore safe" — it is a real drug with real CYP inhibition, and the FDA has explicitly stated it cannot currently approve CBD as a dietary supplement because of liver toxicity and drug-interaction concerns FDA 2023Watkins et al. 2021. Third: "the label tells you the dose" — Bonn-Miller's 2017 JAMA analysis of 84 online CBD extracts found 31% accurately labelled (within ±10%), 43% underlabelled (more CBD than stated), and 26% overlabelled (less CBD than stated); 21% also contained detectable THC despite hemp claims Bonn-Miller et al. 2017. A 2022 follow-up of topicals found ~75% inaccurately labelled Spindle et al. 2022.
practicalities
US legality (federal) for hemp-derived CBD with <0.3% THC was established by the 2018 Farm Bill; state law varies. FDA does not regulate consumer CBD as a supplement and has issued warning letters to companies making explicit disease claims — but does not enforce label-accuracy or quality standards prospectively. Voluntary third-party testing (ISO 17025-accredited labs; certificates of analysis or COAs from companies like ProVerde, SC Labs) is the practical substitute. Cost varies enormously: $0.05–$0.30 per mg CBD is typical, so a "studied" 300 mg/day anxiety dose runs roughly $450–$2,700/year; a typical 25 mg gummy regimen runs $200–$800/year. Insurance covers Epidiolex (prescription, for approved epilepsy indications only); nothing covers consumer products.
failure-modes
Most failure modes trace to one of three: dose too low (taking 10–25 mg when the studied effective range is 100s of mg), product contains less CBD than the label says (the Bonn-Miller and Spindle product audits suggest this happens to roughly 1 in 4 buyers) Bonn-Miller et al. 2017Spindle et al. 2022, or the product is largely placebo-driven and the placebo wears off. A real but smaller fourth bucket: undetected drug interactions — a patient quietly raises plasma levels of their other meds and attributes side effects to the meds or to other causes Brown & Winterstein 2019.
alternatives
For anxiety: well-evidenced alternatives include CBT, exercise, SSRIs (chronic) and buspirone or hydroxyzine (acute) — all with stronger trial bases than CBD. For sleep: sleep hygiene, CBT-I (gold standard for insomnia), and short-course pharmacology under clinician care. For chronic pain: graded exercise, physical therapy, NSAIDs, duloxetine (for some chronic pain syndromes), and — where appropriate — clinician-supervised cannabis with meaningful THC content has stronger trial signal than CBD isolate Mücke et al. 2018.
stakes
The cost case writes itself: a population using a product that probably isn't doing what they think it's doing, frequently from products whose labels don't match contents, sometimes raising plasma levels of medications they aren't told to mention to a prescriber. Per-person cost is real (hundreds to thousands per year) and aggregate spend is in the billions — a transfer from household budgets to retailers with neither a clinician filtering use nor regulatory scrutiny of product. The clinical stakes concentrate in a smaller group: patients on warfarin, clobazam, certain statins, tacrolimus, or oncology regimens who add CBD without telling anyone Brown & Winterstein 2019.
payoff
Honest payoff for the average user is small. Acute anxiety reduction is real at 300–600 mg single-dose; chronic anxiolysis at consumer doses is largely unproven. Sleep effects at consumer doses are uncontrolled patient report only. Topical CBD for joint pain may provide localised relief via mechanisms not unique to CBD (the cream's carrier and any menthol/capsaicin add-ons do most of the work). For the smaller population using purified CBD at pharmaceutical doses under clinician supervision (epilepsy), payoff is substantial and well-documented Devinsky et al. 2017.
out-of-scope
Medical cannabis with meaningful THC content (different drug, different evidence base, different risk profile). Hemp seed oil with no CBD content (mislabelling, not the substance). Recreational hemp-derived intoxicants (Δ8-THC, HHC) that proliferated post-2018 Farm Bill in legal grey zones. Epidiolex prescribing for paediatric epilepsy (clinician-led; outside consumer scope).
Credibility range
Optimist case
CBD is a non-intoxicating, low-overt-toxicity cannabinoid with a real mechanism for anxiolysis (5-HT1A partial agonism, anandamide reuptake modulation) that has produced clean acute-anxiety effects in adequately designed trials Bergamaschi et al. 2011Linares et al. 2019; it is FDA-approved as an anticonvulsant; clinicians publish case series showing real-world anxiety/sleep response at sub-pharmacological doses Shannon et al. 2019; community signal — tens of millions of users sustained over years — is too large to attribute entirely to placebo, even granting the well-known size of placebo in this category. Inverted-U dose-response (300 mg > 900 mg) means some consumer doses are inside the response window for some people. The safety profile in healthy adults is favourable: no addiction signal, no respiratory depression, no overdose mortality in WHO's review WHO 2018.
Skeptic case
The trial evidence at retail doses is essentially absent — Bergamaschi was an acute, single-dose, paradigm-anxiety provocation in 24 patients at 600 mg; Shannon was unblinded; nothing in the literature supports chronic anxiolysis or sleep efficacy at 5–25 mg gummy doses Black et al. 2019. The marketing-vs-evidence gap is enormous and economically motivated (multi-billion-dollar category). Roughly a quarter of products are mis-labelled and many contain detectable THC Bonn-Miller et al. 2017Spindle et al. 2022. CYP inhibition is real and clinically meaningful in the populations most likely to add CBD — older adults on polypharmacy Brown & Winterstein 2019. The FDA has explicitly said it cannot approve CBD as a supplement on safety grounds, citing transaminase elevation in healthy phase I subjects Watkins et al. 2021FDA 2023. The community signal is consistent with a high-placebo, low-mechanism story in an unregulated market.
Author's call
The skeptic case wins for the typical retail consumer at typical retail doses. CBD has a real but narrow signal as an acute anxiolytic at 300+ mg single doses; this almost never reaches the gummy buyer at home. The honest framing is a decide entry, not do or avoid: most retail use is overpriced for its effect, the supply chain is meaningfully variable in quality, and the under-discussed clinical risk is drug interactions in polypharmacy. Where someone has tried other evidence-backed options (CBT-I, SSRIs, exercise) and wants to try CBD as an add-on, the realistic protocol is to (a) buy from a brand publishing third-party COAs, (b) start at doses an order of magnitude above the gummy default — 100+ mg — to even approximate trial conditions, (c) tell their prescriber if on any chronic medication, and (d) plan to stop and reassess after a four-week trial. Evidence rating: 2. Controversy rating: 3 — the marketing-vs-trial gap is the active dispute.
Stakeholder and incentive map
- Hemp/CBD industry. Multi-billion-dollar revenue, near-zero quality regulation. Strong incentive to promote loosely defined wellness claims; weak incentive to fund the trials that would either confirm or refute them.
- Wellness retail (Whole Foods, drugstores, gas stations). Margin product; shelf placement next to vitamins normalises it as a supplement.
- Pharma/Epidiolex (Jazz Pharmaceuticals). Prescription CBD as a high-margin antiepileptic; incentive to keep the pharma version legally distinct from consumer CBD.
- FDA. Awkward position — has stated existing frameworks are inappropriate, asked Congress for a new pathway, and enforces only the most egregious disease claims FDA 2023. The result is a de facto unregulated consumer market.
- Practitioner naturopathic/integrative medicine. Often recommend CBD; recommendation patterns extrapolate well beyond the evidence base.
- Mainstream specialty medicine. Sleep medicine (AASM), pain medicine, and psychiatry guideline bodies do not endorse CBD for their indications; oncology and transplant medicine increasingly warn about interactions.
- User communities. Large self-help communities (Reddit r/CBD, dedicated forums) — generally positive signal, with consistent reports of dose-dependence and product-quality variance that aligns with the trial literature.
Population variability
Five axes matter:
- Dose. The inverted-U seen in Linares 2019 (300 mg helped; 100 and 900 mg didn't) implies an individual response window — the same person likely has a dose that works and doses too low or too high Linares et al. 2019.
- CYP2C19/3A4 polymorphisms. Roughly 2–5% of people of European descent and 15–20% of East Asian populations are CYP2C19 poor metabolisers; in the opposite direction, CYP2D6 ultrarapid metabolisers are common. Both affect CBD pharmacokinetics and the magnitude of drug-drug interactions.
- Polypharmacy. The clinically meaningful population is people on warfarin, clobazam, valproate, tacrolimus, certain statins, SSRIs, or cancer chemotherapy — they bear the interaction risk that most users don't.
- Baseline anxiety severity. The Bergamaschi/Crippa anxiety signal was strongest in clinically anxious patients with a provocation, not in healthy volunteers seeking "general calm."
- Pregnancy / breastfeeding / paediatrics. Insufficient human safety data; FDA advises against; teratogenicity signals in animal studies at high doses.
Knowledge gaps
- Adequately powered chronic-dosing RCTs at consumer-realistic doses (25–100 mg/day) for primary anxiety disorders, primary insomnia, and chronic pain — the trials that would actually settle the consumer question.
- Real-world DDI surveillance — pharmacovigilance data on CBD-related adverse events in patients on chronic prescriptions is thin because most users don't disclose CBD use to prescribers.
- Long-term hepatotoxicity at sub-pharmaceutical doses; the Watkins phase I signal is provocative but at 1500–4500 mg/day — most retail use is two orders of magnitude lower.
- Whether the active ingredient in many "CBD products" that produce effect is in fact CBD vs. accompanying minor cannabinoids (CBG, CBN, THC traces) or terpenes; full-spectrum vs. isolate questions are largely unanswered at trial-grade.
- Bioavailability across product formats — most label dose maps to delivered exposure only via a wide and variable conversion Spindle et al. 2020.
Scope. The brief named anxiety, sleep, pain, the dose gap, CYP drug interactions, label-accuracy/contamination, and the evidence behind common claims — all covered end to end. The entry stays on consumer CBD; Epidiolex (prescription CBD for paediatric epilepsies) is referenced only as the calibration point for what real evidence at therapeutic doses looks like, not as a recommendation. The intoxicating Farm-Bill-loophole cannabinoids (Δ8-THC, HHC) are flagged in out-of-scope as separate-entry candidates.
Action call: decide, not avoid. The honest reading is that retail CBD at retail doses doesn't have evidence for what it's sold for, but the molecule is not a harm-by-itself for most users (the harm cases concentrate in polypharmacy and pregnancy). Framing as avoid overstates; framing as do would be dishonest. decide with a clear "if you do, do it like a trial" protocol fits the evidence.
Rating difficulties.
moodandhealth_short_termboth scored 1 rather than 0 because Bergamaschi 2011 and Linares 2019 are real signals, even though they don't generalise to retail doses. A 0 would have overstated the skeptic case; a 2 would have over-credited dose-mismatched trials.sleepgot 1 on the same grounds, leaning on Shannon 2019 with full acknowledgement that it's uncontrolled.cost_burdenat 2 covers the realistic consumer range ($200–$800/year for the typical gummy user; $450–$2,700/year for someone chasing the studied anxiety dose). 3 felt too high for the gummy user and too low for the high-dose user; 2 is the honest midpoint.controversyat 3 reflects the live marketing-vs-evidence gap rather than a within-science fight. The science is fairly aligned (Cochrane and Lancet Psychiatry both say "insufficient"); the controversy is between trial-grade literature and a multi-billion-dollar consumer category insisting otherwise.applicabilityat 4 uses the avoidance/decision-audience lift frommeta.md§6 — the decision question is relevant to most adults, not just current users, since CBD shelves are mainstream-retail and the "should I bother" question reaches further than current use rates.pullat 4 (internal): low-friction novelty supplement, magnetic to try. The pull/evidence gap (4 vs 2) is the editorial signal that this entry's job is to slow the reader down at the shelf.
Contraindications. Used pregnancy, breastfeeding, blood-thinners. The CYP interaction list is broader than the closed-vocabulary tokens cover (no token exists for "on clobazam," "on tacrolimus," "on chemotherapy," "on certain statins") — those land in the article's contraindications section with the prescriber-disclosure framing instead of in meta. Worth proposing a more granular contraindication vocabulary in a future spec pass.
Dream narrative. Overall score ≈ 18, so the dream narrative was optional. Written anyway on the relief / not-being-conned lever (per dream-narrative.md §3) because the entry's hook is genuinely "stop paying for the thing that mostly doesn't work at the dose you're taking." The tagline ("Trial dose 600 mg. Gummy dose 10. Do the math.") compresses the narrative's sharpest payoff directly.
Future-link candidates. CBT-I (cognitive behavioural therapy for insomnia) — referenced in alternatives and out-of-scope; should cross-link when that entry exists. Medical cannabis with meaningful THC — different drug, separate entry. Δ8-THC / HHC and other hemp-derived intoxicants — flagged in out-of-scope as a separate-entry candidate. Generic "how to evaluate a wellness supplement" methodology — could become a meta-entry; this article is a worked example of the method.
Separate-entry candidates. Epidiolex for treatment-resistant childhood epilepsies (Dravet, Lennox-Gastaut, tuberous sclerosis) deserves its own clinical entry under a respond or decide action — different audience, different decision, different evidence weight. Hemp-derived semi-synthetic intoxicants (Δ8-THC, HHC, THC-O) as their own entry on the Farm-Bill loophole class.
CBD (Cannabidiol) Products
Open bottle, swallow. About as easy as it gets.
A few hundred to a couple thousand dollars a year, depending on whether you want the dose the trials used or the dose on the bottle.
Solid trial data exists — but only for paediatric epilepsy at pharmaceutical doses. For anxiety, sleep, and pain at the doses you'd buy, the trial cupboard is mostly bare.
A real but small acute calming effect at hundreds of milligrams. The 10 mg gummy isn't doing that — the trial dose wasn't.
Sleep claims rest mostly on uncontrolled patient reports. RCTs at the doses you're buying don't really exist.
A real acute anxiolytic at hundreds of milligrams in a public-speaking lab. At gummy doses, mostly placebo and hope.